Peter Tombros, chairman and chief executive officer of VivoQuest, is the newest member of the board of directors at Paradigm Genetics.
Tombros spent 25 years at Pfizer before taking executive positions at Enzon and then VivoQuest in 2001. VivoQuest is a combinational chemistry company.
“Peter brings important operational and commercial expertise in the pharmaceutical sector to our company,” said Heinrich Gugger, president and CEO, at Paradigm. “His vast experience in working with public life sciences companies of all sizes will be invaluable to us.”